Description
The Highly Galactosylated Anti-C5 (Olendalizumab), a biobetter antibody contains with a high level of galactosylation.
Antibody Indication
Neuromyelitis optica (NMO)
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced C5 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
C5
Alternative Names
Eculizumab; soliris; 219685-50-4; h5G1.1; DB01257 C5; complement component 5; complement C5; CPAMD4; anaphylatoxin C5a analog; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4; FLJ17816; FLJ17822; MGC142298;
Gene ID
727
UniProt ID
P01031
Cellular Localization
Extracellular region or secreted
Genecards
1331
Involvement in Disease
Its related pathways are Immune response Lectin induced complement pathway and Signaling by GPCR.
Related Pathways
1.C5 activated by C5 convertase initiates the spontaneous assembly of late complement components C5-c9 to form a membrane attack complex. C5b has a short-term binding site for C6. The C5b-C6 complex is the basis for the assembly of the cleavage complex. 2.C5 anaphylactic shock toxin is derived from the proteolytic degradation of complement C5 and is the mediator of the local inflammatory process. Binding to the receptor C5AR1 can cause a variety of reactions, including intracellular calcium release, smooth muscle contraction, increased vascular permeability, and histamine release from mast cells and basophils (PubMed:8182049). C5a is also a powerful chemokine, which stimulates the movement of polymorphonuclear leukocytes and guides them to migrate to the site of inflammation.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG4, κ
Antibody Clone
Olendalizumab
Description
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to C5. Olendalizumab is a humanized monoclonal antibody that can be potentially used in the treatment of Graft-versus-host disease, Antiphospholipid syndrome.
Antibody Indication
Neuromyelitis optica (NMO)
Neuromyelitis optica (NMO)
